The global population is ageing and this demographic shift has profound effects on haemostasis, notably a progressive tilt ...

Pfizer has launched a second lawsuit against Novo Nordisk over its $9 billion bid for biotech company Metsera. Pfizer accuses ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech ...

Metsera's shareholders are scheduled to meet on November 13 to decide on Novo Nordisk's offer of around $8.5 billion, while Pfizer had previously offered $7.3 billion.

Novo Nordisk asserts its acquisition of Metsera won't pose antitrust problems as it competes with Pfizer for dominance in the ...

Pfizer Inc. accused Novo Nordisk A/S of trying to stifle competition in the weight-loss market by attempting to acquire obesity startup Metsera Inc., the second lawsuit Pfizer has filed in four days ...

Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.

Pfizer files a second lawsuit against Novo Nordisk and Metsera, accusing its rival of blocking a U.S. competitor in the ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Read more here.

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

Pfizer accused Novo Nordisk of trying to stifle competition in the weight-loss market by attempting to acquire obesity startup Metsera, the second lawsuit in four days as Pfizer tries to retain its ...